GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES

Clinical trials for GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES explained in plain language.

Never miss a new study

Get alerted when new GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES trials appear

Sign up with your email to follow new studies for GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New contrast agent may sharpen pituitary tumor detection

Diagnosis Recruiting now

This study tests whether a newer FDA-approved contrast agent, Gadopiclenol, provides clearer images of pituitary lesions on MRI compared to the standard agent, Gadobutrol. Ten adults with known or suspected pituitary lesions will receive both agents in random order, with neither …

Matched conditions: GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES

Phase: PHASE4 • Sponsor: UConn Health • Aim: Diagnosis

Last updated May 17, 2026 05:29 UTC

GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES

Get alerted when new GADOPICLINOL ENHANCED IMAGES VS. GADOBUTROL ENHANCED IMAGES trials appear

New contrast agent may sharpen pituitary tumor detection